Ontology highlight
ABSTRACT: Background
Several (neo)adjuvant treatments for patients with HER2-positive breast cancer have been compared in different randomized clinical trials. Since it is not feasible to conduct adequate pairwise comparative trials of all these therapeutic options, network meta-analysis offers an opportunity for more detailed inference for evidence-based therapy.Methods
Phase II/III randomized clinical trials comparing two or more different (neo)adjuvant treatments for HER2-positive breast cancer patients were included. Relative treatment effects were pooled in two separate network meta-analyses for overall survival (OS) and disease-free survival (DFS).Results
17 clinical trials met our eligibility criteria. Two different networks of trials were created based on the availabi
SUBMITTER: Debiasi M
PROVIDER: S-EPMC5972314 | biostudies-literature | 2018
REPOSITORIES: biostudies-literature